The Impact of Resveratrol Supplementation on Blood Glucose, Insulin, Insulin Resistance, Triglyceride, and Periodontal Markers in Type 2 Diabetic Patients with Chronic Periodontitis

Phytotherapy Research

Volumn 31, Issue 1, 2017, Pages 108-114

  Zare Javid, Ahmad ^a   Hormoznejad, Razie ^a   Yousefimanesh, Hojat allah ^a   Zakerkish, Mehrnoosh ^a   Haghighi zadeh, Mohammad Hosein ^a   Dehghan, Parvin ^b   Ravanbakhsh, Maryam ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

Author keywords

insulin resistance; periodontal disease; resveratrol; type 2 diabetes mellitus

Indexed keywords

GLUCOSE; INSULIN; PLACEBO; RESVERATROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; STILBENE DERIVATIVE;

ADJUVANT THERAPY; ADULT; ARTICLE; CHRONIC PERIODONTITIS; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIODONTAL EXAMINATION; PERIODONTAL POCKET; PERIODONTAL PROCEDURE; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

BLOOD GLUCOSE; CHRONIC PERIODONTITIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; STILBENES; TRIGLYCERIDES;

EID: 84997112366     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5737     Document Type: Article

References (53)

1. Amos AF, Mccarty DJ, Zimmet P. 1997. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14: S7–S85.
2. Bastos AS, Graves DT, Loureiro APDM, et al. 2012. Lipid peroxidation is associated with the severity of periodontal disease and local inflammatory markers in patients with type 2 diabetes. J Clin Endocrinol Metabol 97: E1353–E1362.
3. Bedada SK, Neerati P. 2016. Resveratrol pretreatment affects CYP2E1 activity of chlorzoxazone in healthy human volunteers. Phytother Res 30: 463–8.
4. Bedada SK, Yellu NR, Neerati P. 2016. Effect of resveratrol treatment on the pharmacokinetics of diclofenac in healthy human volunteers. Phytother Res 30: 397–401.
5. Bhatt JK, Thomas S, Nanjan MJ. 2012. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res 32: 537–41.
6. Brasnio P, Molnar GA, Mohash M, et al. 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106: 383–9.
7. Chen L, Luo G, Xuan D, et al. 2012. Effects of non-surgical periodontal treatment on clinical response, serum inflammatory parameters, and metabolic control in patients with type 2 diabetes: a randomized study. J Periodontol 83: 435–443.
8. Crandall JP, Oram V, Trandafirescu G, et al. 2012. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci, glr235 14: 12–223.
9. Dahiya P, Kamal R, Gupta R, Bhardwaj R, Chaudhary K, Kaur S. 2013. Reactive oxygen species in periodontitis. J Indian Soc Periodontol 17: 411–6.
10. Daniel R, Gokulanathan S, Shanmugasundaram N, Lakshmigandhan M, Kavin T. 2012. Diabetes and periodontal disease. J Pharm Bioallied Sci 4: S280–S282.
11. El-Sharkawy H, Aboelsaad N, Eliwa M, et al. 2010. Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 fatty acids and low-dose aspirin. J Periodontol 81: 1635–1643.
12. Faghihzadeh F, Adibi P, Hekmatdoost A. 2015a. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr 114: 796–803.
13. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. 2014. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 34: 837–43.
14. Faghihzadeh F, Hekmatdoost A, Adibi P. 2015b. Resveratrol and liver: a systematic review. J Res Med Sci 20: 797–810.
15. Fordham JB, Naqvi AR, Nares S. 2014. Leukocyte production of inflammatory mediators is inhibited by the antioxidants phloretin, silymarin, hesperetin, and resveratrol. Mediators Inflamm 2014: 938712.
16. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, et al. 2013. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord 13: 47.
17. Grover HS, Luthra S. 2013. Molecular mechanisms involved in the bidirectional relationship between diabetes mellitus and periodontal disease. J Indian Soc Periodontol 17: 292–301.
18. Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J. 2014. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137–149.
19. Hambrock A, De Olivera Franz CB, Hiller S, et al. 2007. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J Biol Chem 282: 3347–3356.
20. Hausenblas HA, Schoulda JA, Smoliga JM. 2015. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus—systematic review and meta-analysis. Mol Nutr Food Res 59: 147–59.
21. Iacopino AM, Cutler CW. 2000. Pathophysiological relationships between periodontitis and systemic disease: recent concepts involving serum lipids. J Periodontol 71: 1375–1384.
22. Izzo AA, Hoon-Kim S, Radhakrishnan R, Williamson EM. 2016. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytother Res 30: 691–700.
23. Kara A, Akman S, Ozkanlar S, et al. 2013. Immune modulatory and antioxidant effects of melatonin in experimental periodontitis in rats. Free Radic Biol Med 55: 21–26.
24. Khazaei M, Karimi J, Sheikh N, et al. 2016. Effects of resveratrol on receptor for advanced glycation end products (RAGE) expression and oxidative stress in the liver of rats with type 2 diabetes. Phytother Res 30: 66–71.
25. Kim EK, Lee SG, Chol YH, et al. 2013. Association between diabetes-related factors and clinical periodontal parameters in type-2 diabetes mellitus. BMC Oral Health 7: 13–64.
26. Mendez-Del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. 2014. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 12: 497–501.
27. Moeintaghavi A, Arab H, Bozorgnia Y, Kianoush K, Alizadeh M. 2012. Non-surgical periodontal therapy affects metabolic control in diabetics: a randomized controlled clinical trial. Aust Dent J 57: 31–37.
28. Movahed A, Nabipour I, Lieben Louis X, et al. 2013. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013: 851267.
29. Munoz, C., Kiger, R., Stephens, J., Kim, J. & Wilson, A. 2001. Effects of a nutritional supplement on periodontal status. Compendium of continuing education in dentistry (Jamesburg, NJ: 1995), 22, 425–8, 430, 432 passim; quiz 440.
30. Nassiri-Asl M, Hosseinzadeh H. 2016. Review of the pharmacological effects of Vitis vinifera (Grape) and its bioactive constituents: an update. Phytother Res 9: 1392–403.
31. O'connor DJ, Wong RW, Rabie AB. 2011. Resveratrol inhibits periodontal pathogens in vitro. Phytother Res 25: 1727–31.
32. Offenbacher S. 1996. Periodontal diseases: pathogenesis. Ann Periodontol 1: 821–878.
33. Park H-J, Jeong S-K, Kim S-R, et al. 2009. Resveratrol inhibits Porphyromonas gingivalis lipopolysaccharide-induced endothelial adhesion molecule expression by suppressing NF-kB activation. Arch Pharm Res 32: 583–591.
34. Poulsen MM, Vestergaard PF, Clasen BF, et al. 2013. High-dose resveratrol supplementation in obese men an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62: 1186–1195.
35. Panckeviciene A, Siudikiene J, Ostrauskas R, Machiulskiene V. 2014. Severity of periodontal disease in adult patients with diabetes mellitus in relation to the type of diabetes. Biomed Pap 158: 117–123.
36. Rizzo A, Bevilacqua N, Guida L, Annunziata M, Romano Carratelli C, Paolillo R. 2012. Effect of resveratrol and modulation of cytokine production on human periodontal ligament cells. Cytokine 60: 197–204.
37. Rodrigues DC, Taba JM, Novaes AB Jr, Souza SL, Grisi MF. 2003. Effect of non-surgical periodontal therapy on glycemic control in patients with type 2 diabetes mellitus. J Periodontol 74: 1361–1367.
38. Seo CH, Kim JB. 2015. Therapeutic potential of resveratrol in type I Gaucher disease. Phytother Res 29: 835–9.
39. Simpson TC, Needleman I, Wild SH, Moles DR, Mills EJ. 2010. Treatment of periodontal disease for glycaemic control in people with diabetes. Aust Dent J 55: 472–474.
40. Soory M. 2012. Inflammatory mechanisms and redox status in periodontal and cardiometabolic diseases: effects of adjunctive nutritional antioxidants and statins. Infect Disord-Drug Targets (Formerly Current Drug Targets-Infectious Disorders) 12: 301–315.
41. Stanko, P. & Izakovicova Holla, L. 2014. Bidirectional association between diabetes mellitus and inflammatory periodontal disease. A review. Biomedical Papers of the Medical Faculty of the University Palacky Olomouc Czech Repub, 158, 35–8.
42. Sun W-L, Chen L-L, Zhang S-Z, Wu Y-M, Ren Y-Z, Qin G-M. 2011. Inflammatory cytokines, adiponectin, insulin resistance and metabolic control after periodontal intervention in patients with type 2 diabetes and chronic periodontitis. Intern Med 50: 1569–1574.
43. Szkudelska K, Szkudelski T. 2010. Resveratrol, obesity and diabetes. Eur J Pharmacol 635: 1–8.
44. Tamaki N, Cristina Orihuela-Campos R, Inagaki Y, Fukui M, Nagata T, Ito HO. 2014. Resveratrol improves oxidative stress and prevents the progression of periodontitis via the activation of the Sirt1/AMPK and the Nrf2/antioxidant defense pathways in a rat periodontitis model. Free Radic Biol Med 75: 222–229.
45. Taylor GW, Borgnakke W. 2008. Periodontal disease: associations with diabetes, glycemic control and complications. Oral Dis 14: 191–203.
46. Telgi RL, Tandon V, Tangade PS, Tirth A, Kumar S, Yadav V. 2013. Efficacy of nonsurgical periodontal therapy on glycaemic control in type II diabetic patients: a randomized controlled clinical trial. J Periodontal Implant Sci 43: 177–182.
47. Timmers S, Hesselink MK, Schrauwen P. 2013. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? Ann N Y Acad Sci 1290: 83–89.
48. Timmers S, Konings E, Bilet L, et al. 2011. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 14: 612–22.
49. Tu YK, D'aiuto F, Lin HJ, Chen YW, Chien K l. 2013. Relationship between metabolic syndrome and diagnoses of periodontal diseases among participants in a large Taiwanese cohort. J Clin Periodontol 40: 994–1000.
50. UysalL T, Gorgulu S, Yagci A, Karslioglu Y, Gunhan O, Sagdic D. 2011. Effect of resveratrol on bone formation in the expanded inter-premaxillary suture: early bone changes. Orthod Craniofac Res 14: 80–7.
51. Vallanou NG, Evangelopoulos A, Kazazis C. 2013. Resveratrol and diabetes. Rev Diabet Stud 10: 236–42.
52. Wu Y-Y, Xiao E, Graves DT. 2015. Diabetes mellitus related bone metabolism and periodontal disease. Int J Oral Sci 7: 63–72.
53. Zare Javid A, Seal CJ, Heasman P, Moynihan PJ. 2013. Impact of a customised dietary intervention on antioxidant status, dietary intakes and periodontal indices in patients with adult periodontitis. J Hum Nutrt Diet 6: 523–32.